Humana Inc. HUM

NYSE · Healthcare · Medical - Healthcare Plans

$389.91

Close on Fri, 20 Nov 2026 · market value $46.8B

What the price is betting on

In line with its record

At $390, the price assumes revenue grows about 11% a year for five years, from $154B to about $236B by FY2030. That is about the same as what analysts expect for the next two years and less than the company's own last three years.

The price assumes11%
Analysts, next two years9.8%
Last 3 years14%

Revenue growth a year. The price figure comes from a reverse DCF at a 8.1% discount rate.

Track it and Parra checks each report against the path, and tells you when revenue falls behind it.

Own more than HUM? Check up to 5 of your stocks at once, free, no account.

0$100B$200B$300B$154B'22'23'24'25Sep '26'26'27'28'29'30What the price needsReportedAnalysts

Both sides

Three stories, three values

Bear

$343

Base

$373

Bull

$410

Today $390

  • Bear $343. Cash flow grows 5% a year for the next 5 years, slower than expected, then slows to long-run growth.
  • Base $373. Cash flow grows 9% a year for the next 5 years, as analysts expect, then slows to long-run growth.
  • Bull $410. Cash flow grows 12% a year for the next 5 years, faster than expected, then slows to long-run growth.

Stories set by rules from the company’s record.

Checkpoints

The revenue the price needs

  1. YearNeedsAnalysts expect
  2. FY2026$158B$163B, on the path
  3. FY2027$175B$174B, on the path
  4. FY2028$193B$190B, on the path
  5. FY2029$214B$202B, below the path
  6. FY2030$236B$213B, below the path

Each year's revenue at 11% growth from $154B in the 12 months to September 2026.

At a glance

Healthcare · Medical - Healthcare Plans · listed on NYSE

Revenue, FY2025
$130B
Growth, 3 years a year
14%
Cash margin
0.3%
Net debt
$8.7B
Shares, 3-year change
−4.9%
Dividend yield
0.9%

What other healthcare prices are betting on

Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.